1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Invega (paliperidone; Janssen) is the 9-hydroxy metabolite of risperidone and thus shares a similar pharmacologic profile with Risperdal. Invega is a D2 and 5-HT2A antagonist, and though it lacks activity on M1 and M3 muscarinic receptors, it also blocks a1 and a2 adrenergic, and H1 histaminergic receptors.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Invega including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Invega for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Invega performance
- Obtain sales forecast for Invega from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Invega (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Diagnosis 14
4.1.1 Subjective Assessments 15
4.1.2 Disease Subtypes 16
4.2 Treatment Overview 19
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 21
4.2.2 Maintenance Treatment of Schizophrenia 22
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Invega (paliperidone) 26
6.1 Overview 26
6.2 Efficacy 28
6.3 Safety 28
6.4 SWOT Analysis 29
6.5 Forecast 29
7 Appendix 30
7.1 Bibliography 30
7.2 Abbreviations 32
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 Diagnosis and Treatment Rates 33
7.4.2 Adherence Rates 34
7.4.3 General Pricing Assumptions 34
7.4.4 Drug Assumptions 35
7.4.5 Generic Erosion 36
7.5 Key Opinion Leaders 37
7.6 About the Authors 38
7.6.1 Author 38
7.6.2 Reviewers 38
7.6.3 Global Head of Healthcare 39
7.7 About GlobalData 40
7.8 Disclaimer 40

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 13
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 16
Table 3: Development-Based Classification of Antipsychotic Drugs 19
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 20
Table 5: Guidelines for the Treatment of Schizophrenia 21
Table 6: Leading Branded Treatments for Schizophrenia, 2013 25
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 25
Table 8: Product Profile - Invega 27
Table 9: Invega SWOT Analysis, 2013 29
Table 10: Global Sales Forecast ($m) for Invega, 2012-2022 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Therapy Market in the US

  • January 2017
    7 pages
  • Therapy  

    Therapy  

  • United States  

View report >

Therapy Market in the US

  • January 2017
    16 pages
  • Therapy  

  • United States  

View report >

Diabetes Statistics

3 days ago

Related Market Segments :

Therapy
Antipsychotic

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.